282 related articles for article (PubMed ID: 29413286)
1. Radiation Dose to the Thoracic Vertebral Bodies Is Associated With Acute Hematologic Toxicities in Patients Receiving Concurrent Chemoradiation for Lung Cancer: Results of a Single-Center Retrospective Analysis.
Barney CL; Scoville N; Allan E; Ayan A; DiCostanzo D; Haglund KE; Grecula J; Williams T; Xu-Welliver M; Otterson GA; Bazan JG
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(3):748-755. PubMed ID: 29413286
[TBL] [Abstract][Full Text] [Related]
2. Thoracic Vertebral Body Irradiation Contributes to Acute Hematologic Toxicity During Chemoradiation Therapy for Non-Small Cell Lung Cancer.
Deek MP; Benenati B; Kim S; Chen T; Ahmed I; Zou W; Aisner J; Jabbour SK
Int J Radiat Oncol Biol Phys; 2016 Jan; 94(1):147-154. PubMed ID: 26700708
[TBL] [Abstract][Full Text] [Related]
3. Normal tissue complication probability modeling of acute hematologic toxicity in patients treated with intensity-modulated radiation therapy for squamous cell carcinoma of the anal canal.
Bazan JG; Luxton G; Mok EC; Koong AC; Chang DT
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):700-6. PubMed ID: 22414279
[TBL] [Abstract][Full Text] [Related]
4. Increasing Radiation Dose to the Thoracic Marrow Is Associated With Acute Hematologic Toxicities in Patients Receiving Chemoradiation for Esophageal Cancer.
Fabian D; Ayan A; DiCostanzo D; Barney CL; Aljabban J; Diaz DA; Miller ED; Wuthrick E; Williams TM; Bazan JG
Front Oncol; 2019; 9():147. PubMed ID: 30931257
[No Abstract] [Full Text] [Related]
5. Impact of chemotherapy on normal tissue complication probability models of acute hematologic toxicity in patients receiving pelvic intensity modulated radiation therapy.
Bazan JG; Luxton G; Kozak MM; Anderson EM; Hancock SL; Kapp DS; Kidd EA; Koong AC; Chang DT
Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):983-91. PubMed ID: 24161422
[TBL] [Abstract][Full Text] [Related]
6. Lumbosacral spine and marrow cavity modeling of acute hematologic toxicity in patients treated with intensity modulated radiation therapy for squamous cell carcinoma of the anal canal.
Cheng JC; Bazan JG; Wu JK; Koong AC; Chang DT
Pract Radiat Oncol; 2014; 4(3):198-206. PubMed ID: 24766688
[TBL] [Abstract][Full Text] [Related]
7. Effects of Chemotherapy Regimen and Radiation Modality on Hematologic Toxicities in Patients Receiving Definitive Platinum-based Doublet Chemoradiation for Non-Small Cell Lung Cancer.
Tang C; Lee MS; Gomez D; Levy LB; Zhuang Y; Lu C; Liao Z; Komaki R
Am J Clin Oncol; 2017 Dec; 40(6):625-630. PubMed ID: 26165417
[TBL] [Abstract][Full Text] [Related]
8. Lumbar-sacral bone marrow dose modeling for acute hematological toxicity in anal cancer patients treated with concurrent chemo-radiation.
Franco P; Ragona R; Arcadipane F; Mistrangelo M; Cassoni P; Rondi N; Morino M; Racca P; Ricardi U
Med Oncol; 2016 Dec; 33(12):137. PubMed ID: 27815805
[TBL] [Abstract][Full Text] [Related]
9. Impact of Radiation Dose to the Host Immune System on Tumor Control and Survival for Stage III Non-Small Cell Lung Cancer Treated with Definitive Radiation Therapy.
Ladbury CJ; Rusthoven CG; Camidge DR; Kavanagh BD; Nath SK
Int J Radiat Oncol Biol Phys; 2019 Oct; 105(2):346-355. PubMed ID: 31175902
[TBL] [Abstract][Full Text] [Related]
10. Long-Term Bone Marrow Suppression During Postoperative Chemotherapy in Rectal Cancer Patients After Preoperative Chemoradiation Therapy.
Newman NB; Sidhu MK; Baby R; Moss RA; Nissenblatt MJ; Chen T; Lu SE; Jabbour SK
Int J Radiat Oncol Biol Phys; 2016 Apr; 94(5):1052-60. PubMed ID: 27026312
[TBL] [Abstract][Full Text] [Related]
11. Three-Dimensional Radiation Therapy to the Primary Tumor With Concurrent Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer: Results of a Multicenter Phase 2 Study From PPRA-RTOG, China.
Su S; Li T; Lu B; Wang X; Li J; Chen M; Lu Y; Bai Y; Hu Y; Ouyang W; Ma Z; Li Q; Li H; Wang Y
Int J Radiat Oncol Biol Phys; 2015 Nov; 93(4):769-77. PubMed ID: 26530745
[TBL] [Abstract][Full Text] [Related]
12. Pulmonary toxicity in Stage III non-small cell lung cancer patients treated with high-dose (74 Gy) 3-dimensional conformal thoracic radiotherapy and concurrent chemotherapy following induction chemotherapy: a secondary analysis of Cancer and Leukemia Group B (CALGB) trial 30105.
Salama JK; Stinchcombe TE; Gu L; Wang X; Morano K; Bogart JA; Crawford JC; Socinski MA; Blackstock AW; Vokes EE;
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e269-74. PubMed ID: 21477940
[TBL] [Abstract][Full Text] [Related]
13. Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis.
Palma DA; Senan S; Tsujino K; Barriger RB; Rengan R; Moreno M; Bradley JD; Kim TH; Ramella S; Marks LB; De Petris L; Stitt L; Rodrigues G
Int J Radiat Oncol Biol Phys; 2013 Feb; 85(2):444-50. PubMed ID: 22682812
[TBL] [Abstract][Full Text] [Related]
14. Radiation pneumonitis after definitive concurrent chemoradiotherapy with cisplatin/docetaxel for non-small cell lung cancer: Analysis of dose-volume parameters.
Katsui K; Ogata T; Watanabe K; Katayama N; Kuroda M; Kiura K; Hiraki T; Maeda Y; Toyooka S; Kanazawa S
Cancer Med; 2020 Jul; 9(13):4540-4549. PubMed ID: 32364685
[TBL] [Abstract][Full Text] [Related]
15. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
[TBL] [Abstract][Full Text] [Related]
16. Randomized phase II study of concurrent cisplatin/etoposide or paclitaxel/carboplatin and thoracic radiotherapy in patients with stage III non-small cell lung cancer.
Wang L; Wu S; Ou G; Bi N; Li W; Ren H; Cao J; Liang J; Li J; Zhou Z; Lv J; Zhang X
Lung Cancer; 2012 Jul; 77(1):89-96. PubMed ID: 22418243
[TBL] [Abstract][Full Text] [Related]
17. Acute severe radiation pneumonitis among non-small cell lung cancer (NSCLC) patients with moderate pulmonary dysfunction receiving definitive concurrent chemoradiotherapy: Impact of pre-treatment pulmonary function parameters.
Zhou Y; Yan T; Zhou X; Cao P; Luo C; Zhou L; Xu Y; Liu Y; Xue J; Wang J; Wang Y; Lu Y; Liang B; Gong Y
Strahlenther Onkol; 2020 Jun; 196(6):505-514. PubMed ID: 31828393
[TBL] [Abstract][Full Text] [Related]
18. The Role of Thoracic Vertebral Body Dosimetry in Minimizing Acute Hematologic Toxicities of Patients With Non-Small Cell Lung Cancer Receiving Lung Radiation Therapy and Immunotherapy.
Ma J; Li Y; Yu H; Zhang J; Zhang Y; Verma V; Chen H; Qin X; Zhai X; Shang S; Shangguan J; Wang R; Tian C; Wang F; Yu J; Chen D
Int J Radiat Oncol Biol Phys; 2024 May; 119(1):78-89. PubMed ID: 38040058
[TBL] [Abstract][Full Text] [Related]
19. Analysis of the risk factors for myelosuppression after concurrent chemoradiotherapy for patients with advanced non-small cell lung cancer.
Jiang N; Chen XC; Zhao Y
Support Care Cancer; 2013 Mar; 21(3):785-91. PubMed ID: 22936496
[TBL] [Abstract][Full Text] [Related]
20. Acute esophagus toxicity in lung cancer patients after intensity modulated radiation therapy and concurrent chemotherapy.
Kwint M; Uyterlinde W; Nijkamp J; Chen C; de Bois J; Sonke JJ; van den Heuvel M; Knegjens J; van Herk M; Belderbos J
Int J Radiat Oncol Biol Phys; 2012 Oct; 84(2):e223-8. PubMed ID: 22560551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
